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Quadruplexes DNA are present in telomeric DNA as well as in several cancer-related gene promoters and hence affect
gene expression and subsequent biological processes. The conformations of G4 provide selective recognition sites for
small molecules and thus these structures have become important drug-design targets for cancer treatment.
The DNA G-quadruplex binding pentacyclic acridinium salt RHPS4 (1) has many pharmacological attributes of an ideal
telomere-targeting agent but has undesirable off-target liabilities. Notably a cardiovascular effect was evident in a
guinea pig model, manifested by a marked and sustained increase in QTcB interval. In accordance with this, significant
interaction with the human recombinant β2 adrenergic receptor, and M1, M2 and M3 muscarinic receptors was
observed, together with a high inhibition of the hERG tail current tested in a patch clamp assay.
Two related pentacyclic structures, the acetylamines (2) and (3), both show a modest interaction with β2 adrenergic
receptor, and do not significatively inhibit the hERG tail current while demonstrating potent telomere on-target
properties comparing closely with 1. Of the two isomers, the 2-acetyl-aminopentacycle (2) more closely mimics the
overall biological profile of 1 and this information will be used to guide further synthetic efforts to identify novel
variants of this chemotype, to maximize on-target and minimize off-target activities.
Consequently, the improvement of toxicological profile of these compounds could therefore lead to the obtainment of
suitable molecules for clinical development offering new pharmacological strategies in cancer treatment.
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Telomeric DNA is protected and maintained at the ends
of chromosomes by the action of the enzyme telomerase.
Whilst the shortening of DNA telomeres during re-
peated cell division is a natural part of the cellular age-
ing mechanism, one of the hallmarks of cancer is the
expression of telomerase by cancer cells which allows
them to maintain telomeric length and adopt immortal
characteristics [1,2]. Telomerase requires a single-stranded
DNA primer as substrate for the addition of telomeric re-
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reproduction in any medium, provided the orstranded tract, also called G-overhang, can fold into four-
stranded G-quadruplex (G4) structures consisting of G-
tetrads coordinated around a monovalent cation [4,5]. G4
stabilization, deny access of telomerase to its substrate,
representing a valid tool for telomerase targeted approach
in cancer therapy [6]. Nevertheless, for direct telomerase
inhibition, a time-dependent response is observed, related
to the basal length of the telomeres, due to the slow attri-
tion of telomeres experienced after each cell division, thus
limiting the efficacy of agents designed to inhibit telomer-
ase alone [7-9]. The extremely rapid and potent cytotoxic
effect triggered by G4 ligands interacting with telomeric
DNA sequences (‘Telomere Targeting Agents’: TTAs) is
explained by a dual mechanism of action. On one hand
the inhibition of telomerase, and, on the other hand,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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complex which stabilises and protects the ends of chro-
mosomes from being recognized as double-strand breaks
[7,8]. The presence of G4 structures has been recently
showed in non telomeric regions, as already hypothesized
on the base of predictive studies [10]. In particular, G4
forming regions were already found in the promoter of
several cancer related genes (c-myc, bcl2, hif1, hTERT),
and for some of those genes, a transcriptional inhibitory
function was attributed to these structures. Consequently,
G4 targeting molecules could have additional extra-
telomeric features, which could improve their potential as
anti-cancer agents.
The pentacyclic quinoacridinium salt RHPS4 (1: Figure 1)
has many of the attributes of an ideal TTA. We have
shown previously by NMR studies that the agent stacks
above and below the G3 core of a (TTAGGGT)4 parallel-
stranded quadruplex; [11] it binds with high efficiency to
the h-Tel DNA sequence as measured by surface plasmon
resonance [11], circular dichroism and ESI-MS [12,13]; it
is an active inhibitor of telomerase (IC50 0.33 μM) as re-
vealed in a Trap assay [14] and disrupts the shelterin com-
plex of the telomere with the liberation of the POT-1
protein [15]. The compound shows high efficacy in in-
vitro tumor cell growth inhibition assays [14-16] and is
particularly effective against human tumor xenografts in
combination with taxol, [17] irinotecan [18] and, spectacu-
larly so, in a triple combination with irinotecan and a
PARP-1 inhibitor [19]. In addition, the compound has
some desirable chemical and pharmaceutical properties
such as ease of synthesis by a two-step route [20], high
solubility, stability, and predicted freedom from metabolic
liabilities [21]. However, in this paper we report that the
prototypic quinoacridinium salt 1 also exhibits some un-
desirable off-target effects, but that these effects can be
ameliorated to some extent in related non-fluorinated
compounds 2 and 3 without compromising on-target
properties. These physico-chemical and pharmacological
studies offer hope that a suitable clinical candidate might
yet emerge based on this pentacyclic chemotype.Figure 1 Structures of quinoacridinium salt RHPS4 (1) and related cheMethods
Chemistry
3,11-Difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium
metho-sulfate 1 was prepared from 6-fluoro-1,2-dimethyl-
quinolinium methosulfate 7 as described [17]. 2-Acetyl-
amino- (2) and 3-acetylamino-8,13-dimethyl-8H-quino[4,3,




Ethyl trifloromethosulfate (1 mL) was added to a solution
of 3,11-difluoro-6,8-dimethyl-8H-quino[4,3,2-kl]acridine (6;
0.05 g, 0.15 mmol) in CHCl3 (2 mL) under nitrogen. The
mixture was heated at 140°C in a sealed tube for 3 days,
cooled and solvent evaporated. The residue was purified by
column chromatography on silica gel (5% MeOH/DCM) to
leave the salt (8) as a bright red solid (20%), mp >250°C
(decomp.); IR (νmax) 1620, 1583, 1533, 1475, 1429, 1255,
1028 cm-1; 1H NMR (DMSO-d6) δ 8.58 (1H, dd, J = 10.0,
2.9 Hz), 8.43 (1H, s), 8.26 (2H, m), 8.21 (1H, dd, J = 9.4,
4.9), 8.04 (1H, m), 8.01 (1H, s), 7.78 (1H, m), 5.12 (2H, q, J
= 6.8 Hz, N-CH2), 3.17 (3H, d, J = 5.1 Hz), 2.78 (3H, s, N-
CH3), 1.15 (3H, t, J = 6.8 Hz, N-CH2 CH3); m/z 361.1 (M
+).
Cardiovascular effects of anaesthetised Guinea pig
After anaesthesia with approximately 40 to 60 mg/kg (i.p.)
sodium pentobarbitone, a jugular vein was cannulated for
administration of the vehicle or test substance. Arterial
blood pressure (systolic, diastolic and mean) was mea-
sured via a catheter inserted into the carotid artery, heart
rate was derived electronically from the pressure wave-
form and a sample of arterial blood determined blood
gases (PO2 and PCO2), O2 saturation, standard bicarbonate
(HCO3), pH and base excess before the start of the experi-
ment. Electrocardiogram (ECG) limb electrodes recorded
the standard lead II configuration and QTcB interval (cal-
culated as QTcB =QT/(√RR)). The animal was allowed to
stabilise after completion of the surgical preparation for a
period of at least 15 min. Then, after a further 10 minmotypes (2 and 3).
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dynamic variables, the test substance or vehicle was ad-
ministered intravenously as 3 iv infusions with each
administration separated by 60 min.
Receptor inhibition
For hERG study, HEK293 cells were cultured (1–7 days) in
DMEM/GlutaMax-1 + 10% FBS and were plated on
collagen-coated dishes (about 2×104 cells/dish). The cell
was held at -80 mV. A 50-millisecond pulse to -40 mV was
delivered to measure the leaking currents, which were
subtracted from the tail currents online. Then the cell was
depolarized to +20 mV for 2 seconds, followed by a second
pulse to -40 mV for 1 second to reveal the tail currents.
This paradigm was delivered once every 5 seconds to moni-
tor the current amplitude. After the current amplitude
stabilized, the test compound was delivered to the extracel-
lular medium by a rapid solution changer perfusion system.
During perfusion, the cell was repetitively stimulated with
the protocol described above, and the current amplitude
was continuously monitored. Data were acquired and ana-
lyzed by using pClamp (Axon Instruments), and Excel
(Microsoft), and are reported as mean and individual
values. The degree of inhibition (%) was obtained by meas-
uring the tail current amplitude before and after drug
superfusion (the difference current was normalized to con-
trol and multiplied by 100 to obtain the percent of inhib-
ition). Concentration (log) response curves were fitted to a
logistic equation (three parameters assuming complete
block of the current at very high test compound concentra-
tions) to generate estimates of the 50% inhibitory concen-
tration (IC50). The concentration-response relationship of
each compound was constructed from the percentage re-
ductions of current amplitude by sequential concentrations.
β2-adrenergic receptor CHO expressing cells were used for
the receptor inhibition assay as described [22]. The results
are expressed as a percent of inhibition of control specific
binding (100 - (measured specific binding/control specific
binding) × 100)) obtained in the presence of the test com-
pounds. The specific ligand binding to the receptors is de-
fined as the difference between the total binding and the
nonspecific binding determined in the presence of an ex-
cess of unlabelled ligand. All the in-vivo experiments were
carried out at the Regina Elena Cancer Institute. All pro-
cedures involving animals and care were performed in
compliance with our institutional animal care guidelines
and with international directives (directive 2010/63/EU of
the European parliament and of the council; Guide for the
Care and Use of Laboratory Animals, United States
National Research Council, 2011).
Biosensor-surface plasmon resonance (SPR) studies
Oligonucleotides 5′-biotin-d[AG3(T2AG3)3] quadruplex
and 5′-biotin-CGA3T3C(CT)2GA3T3CG were purchasedfrom Midland Certified Reagent Company (Midland, TX).
Purification of DNA, preparation of solutions, collection
of data, and analysis of results were conducted according
to methods adopted in an earlier study [11].
CD spectroscopy
CD spectra were recorded on an Applied Photophysics
Pi-Star-180 spectrophotometer (Applied Photophysics
Ltd, Surrey, UK). The optical system was configured
with a 75 W Xe lamp, circular light polarizer and end-
mounted photomultiplier. The instrument had previ-
ously been calibrated with (D)-camphorsulfonic acid.
Temperature was regulated using a Neslab RTE-300 cir-
culating programmable water bath (Neslab Inc). CD
spectra were recorded at 298 K in a 10 mm path length
cell over a wavelength range of 215–345 nm in steps of
either 1 0r 2 nm, with 3 nm entrance/exit slit widths:
the number of counts was set to 10,000 with adaptive
sampling set to 500,000. The spectra were corrected by
subtracting the spectrum of the same buffer solution of
100 mM potassium chloride and 10 mM potassium
phosphate at pH 7.0. Annealing and melting profiles
were recorded using a thermoelectric temperature con-
troller (Melcor) on 4 μM DNA samples with and without
3.5 mol.equiv. of ligands using 0.5 K temperature incre-
ments and a cooling or heating rate of 0.2 K/min over
the temperature range 298-368 K.
Cells and culture conditions
BJ fibroblasts expressing hTERT (BJ-hTERT) or hTERT
and SV40 early region (BJ-EHLT), were obtained as pre-
viously reported [15]. Cells were grown in Dulbecco
Modified Eagle Medium (D-MEM, Invitrogen Carlsbad,
CA, USA) supplemented with 10% fetal calf serum,
2 mM L-glutamin and antibiotics.
Proliferation assay
5 × 104 cells were seeded in 60-mm Petri plates (Nunc,
MasciaBrunelli, Milano, Italy) and 24 h after plating,
0.5 μM of freshly dissolved compound was added to the
culture medium. Cell counts (Coulter Counter, Kontron
Instruments, Milano, Italy) and viability (trypan blue dye
exclusion) were determined daily, from day 2 to day 8
of culture.
Immunofluorescence
Cells were fixed in 2% formaldehyde and permeabilized
in 0.25% Triton X100 in PBS for 5 min at room
temperature. For immunolabeling, cells were incubated
with primary antibody, then washed in PBS and incu-
bated with the secondary antibodies. The following pri-
mary antibodies were used: pAb and mAb anti-TRF1
(Abcam Ltd.; Cambridge UK); mAb (Upstate, Lake Placid,
NY) and pAb anti-γH2AX (Abcam). The following
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anti Rabbit, FITC conjugated Goat anti Mouse (Jackson
ImmunoResearch Europe Ltd., Suffolk, UK). Fluores-
cence signals were recorded by using a Leica DMIRE2
microscope equipped with a Leica DFC 350FX camera
and elaborated by a Leica FW4000 deconvolution soft-
ware (Leica, Solms, Germany). This system permits to
focus single planes inside the cell generating 3D high-
resolution images. For quantitative analysis of γH2AX
positivity, 200 cells on triplicate slices were scored. For
TIF’s analysis, in each nucleus a single plane was ana-
lyzed and at least 50 nuclei per sample were scored.
Fluorescence in situ hybridization (FISH)
For metaphase chromosome preparation cells were
treated with demecolcine (Sigma, Milan, Italy) 0.1 mg/ml
for 4 h and then harvested and washed in 75 mM
KCl for 5 min at 37°C. After centrifugation cells were
fixed in MeOH/acetic acid 3:1 overnight and then
spread on slides. Hybridization with rhodamine-
coupled PNA was performed as described [23]. For
each sample 20 metaphases per slice on triplicate
were scored. Images of the metaphases were captured
with a 100 × objective.Figure 2 (I) NaH in DMF, Me2SO4; (II) 5-fluoro-2-pivalamidophenylbor
(IV) Me2SO4 in MeNO2, reflux; (V) Et3N in nitrobenzene, 120°C, 24 h; (Chromatin immunoprecipitaion assay (ChIP)
BJ-EHLT fibroblasts were treated for 24 hrs with 0.5 μM
of the compound. ChIP assay was performed as previ-
ously described [24]. The following antibodies were
used: pAb anti-TRF1 (Santa Cruz Biotechnology, Santa
Cruz, Ca); mAb anti-TRF2 (Imgenex, San Diego, CA);
pAb anti-POT1 (Abcam). mAb anti-β-actin (Sigma) was
used as negative control of the ChIP assay.
Results and discussion
Synthesis of quino [4,3,2-kl] acridinium salts
We have previously reported two routes to the penta-
cyclic acridinium salt 1. The less efficient involved con-
struction of the 1-bromo-7-fluoro-3-methylacridone 4
which was processed to the intermediate N-methylacridone
5 where the pivaloyl-protected fluoroaniline fragment was
attached by a Suzuki coupling.18 Deprotection and cycli-
zation of 5 in EtOH–5 M HCl yielded the pentacycle 6 in
65% yield (Figure 2). Methylation of 5 with dimethyl
sulphate in refluxing nitromethane furnished the dark red
pentacyclic salt 1 (48%). However the overall yield of 1
from suitable precursors to 4 was disappointingly low at <
10% [20]. A more practicable route for the large-scale syn-
thesis of salt 1 involved the multi-step, but ‘one-pot’ ,onic acid, Pd(PPh3)4, NaHCO3, aq. DME, 80°C; (III) EtOH, 5 M HCl;
VI) EtOSO2CF3, CHCl3, 140°C, 72 h.
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to 1 with triethylamine in nitrobenzene at 120°C in an opti-
mized 33% yield [21]. This surprising process was adapted
from a synthesis of salts related to 1 by Ozczapowicz and
colleagues in 1988 [21].
Efforts to prepare higher alkyl homologues of 1 were
only partially successful presumably because access by
larger alkylating moieties at N-13 of pentacycle 6 were
impeded by hydrogen atoms at positions 1 and 12 (for
numbering system see Figure 1): thus whereas the N-
ethyl quaternary salt 8 (20%) could be prepared with dif-
ficulty by heating 6 and ethyl trifluoromethane sulfonate
in chloroform under nitrogen at 140°C in a sealed tube
for 3 days, it was not possible to prepare n-propyl or i-
propyl homologues of 6 under a range of forcing condi-
tions. The isomeric N-acetyl compounds 2 and 3 were
prepared starting from the 2-aminoquinoacridine 9 or 3-
chloroquinoacridine 10, respectively, in several steps
according to our previously published work [25].
Toxicity of quinoacridinium salt 1
Initial in vivo evaluation of 1, in human tumor xeno-
grafted nude mice, did not indicate any toxicity at effica-
cious doses, as no toxic deaths or body weight loss was
observed during or after treatment. Furthermore, histo-
logical analysis, done at the end of treatment with 1, re-
vealed no evidence of lesions or morphological alterations
in the organs and tissues examined. Nevertheless, just
after 1 administration, a marked but reversible hypoten-
sion was observable, accompanied by a heart rate and car-
diac output decrease in the treated compared to the
control mice [18].
Several limitations exist in the use of mouse and rat
models for the study of cardiotoxic effects in pharmacol-
ogy, which regard differences in myocardial function
compared to the human heart [26]. To better address
the question of cardiac toxicity of 1, more detailed study
was conducted in anaesthetised guinea pigs, where appli-
cation of an infusion pump allowed for a constant rate
of drug delivery over a period of up to 1 hour; this
method also allowed for repeated administration of
1, with dose escalation, in the same animal over a
3 hour period. At escalating doses of 0.25, 0.5 and
1 mg/kg, each administered to the same guinea pig (n = 3)
over a 5 minute period, and with each dose separated by a
period of 1 hour (cumulative dose 1.75 mg/kg), there was
a dose-related decrease in heart rate during the course of
the experiment (Figure 3a). Significantly, a marked and
sustained decrease in the QTcB interval (QT interval
corrected for heart rate) was observed at all doses
(Figure 3b).
To investigate the molecular bases of cardio toxicity, the
agent was tested for its potential to interact with a panel
of 54 pharmacological receptors, the majority beinghuman recombinant receptors (Cerep ExpresSProfile
screen) (www.cerep.fr). At a concentration of 1 μM signifi-
cant interaction (% inhibition of ligand binding >95%) was
demonstrated with the β2 adrenergic receptor (Table 1),
and M1, M2 and M3 muscarinic receptors (data not
shown); of more concern, compound 1 was also classified
as a highly potent inhibitor of the hERG (human Ether-a-
go-go Related Gene) tail current when tested in a conven-
tional patch clamp assay (100% inhibiton at 10 μM,
Table 1), which can be predictive of possible cardiovascu-
lar complications in clinical development [27].
Ligand redesign to minimize off target effects
The potent hERG inhibition compromised the accept-
ability of 1 as a clinical candidate, despite this agent hav-
ing many of the attributes of an ideal pharmaceutical
[28]. Two strategies have been adopted in an attempt to
minimize the hERG interaction: (i) sterically masking
the (delocalized) positive charge on the acridinium cat-
ion by increasing the size of the substituent at position
13 as in compound 8; and (ii) evaluating compounds 2
and 3 as prototypes of two series of isomeric pentacyclic
acridinium salts of the same chemotype as 1.
hERG tail current inhibition was used as a marker of
potential off-target liabilities. The prototypic agent 1 po-
tently inhibited hERG by 100% at 10 μM (IC50 0.2 μM)
(Table 1); inhibition of hERG was reduced to 43% at
10 μM (IC50 3.7 μM) in the 2-acetylaminoquinoacridinium
iodide 2 and to 18% by 13-ethyl homologue 8, while the
least potent hERG inhibitor (IC50 18 μM) was the 3-
acetylamino isomer 3, a 90-fold improvement over 1. The
marked improvement of 8 over 1, was paralled by a >10-
fold reduction in the on-target effect against the h-Tel
DNA sequence as measured by surface plasmon reson-
ance (see below) suggesting that increasing the size of the
onium head was not a fruitful developmental approach,
for these reason the compound 8 was excluded from fur-
ther studies.
The interaction with β2-adrenergic receptor was deter-
mined by a binding assay of 1, 2 and 3 to the transgenic
β2-adrenegic receptor expressed on the surface of CHO
cells. Inhibition of receptor was reported as inhibition of
control specific binding (100 - (measured specific bind-
ing/control specific binding) × 100) obtained in the pres-
ence of the test compounds. A decay of 75% and 70% of
receptor inhibition is observed comparing 1 to 2 and 3
compounds respectively (Table 1). These results indicate
that potential toxicities in this chemotype, as predicted
by hERG and β2-adrenergic receptor interactions, can
be addressed by suitable molecular modification.
On target-effects: ligand-quadruplex interactions
The Surface Plasmon Resonance (SPR) technique is a
powerful tool to compare binding affinities for G-
Figure 3 Cardiovascular effects of 1. Effect of 1 on Heart Rate (a) and QTcB Interval (b) in the Anaesthetized Guinea Pig Following Escalating
Intravenous Doses of 0.25 mg/kg, 0.5 mg/kg and 1.0 mg/kg (Cumulative Dose: 1.75 mg/kg). Sequential doses of 0.25 mg/kg, 0.5 mg/kg and
1.0 mg/kg to each of three guinea pigs. Time interval between doses: 60 minutes. Plots represent mean data from three animals.
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sequence comprising 5′-d[AGGG(TTAGGG)3]-3′ is im-
mobilised on a sensor chip surface, binding of drug elicits
a refractive index change at the surface, and hence the re-
fractive light angle at which SPR is observed. SPR can also
be used to analyze the binding of compounds to an alter-
nating hairpin duplex sequence thus allowing accurateTable 1 On and off target profile of pentacyclic acridinium sa










aBuffer solution: 10 mM HEPES, 200 mM KCl, 3 mM EDTA and 0.01% P20 surfactant
bHuman telomeric sequence 5′-d[AGGG(TTAGGG)3]-3′.
c5′-d[CGA3T3C(CT)2GA3T3CG]-3′ hairpin sequence.
dThermal stability data for h-Tel (anti-parallel) determined by CD in the absence and
eTm for unaligned h-Tel = 70 ± 3.comparisons of the relative affinities of compounds for
DNA G-quadruplex and DNA duplex structures. We
have reported earlier preliminary equilibrium binding
affinities of compounds 1–3 indicating that these com-
pounds bind more strongly to the h-Tel quadruplex se-
quence; in the earlier case a duplex sequence comprising
an alternating GC eight base pair hairpin was used [11]. Inlts 1, 2 and 3
On-target effects: ligand-quadruplex interaction
rface plasmon resonancea (K x 107 M-1) CD study thermal
stabilityd
lex (Q) DNAb Duplex (D) DNAc Ratio Q/D Tm/°C ΔTm
e
0.83 0.06 13.8 86 ± 3 16
1.5 0.04 37.5 89 ± 3 19
0.8 0.07 11.4 85 ± 3 15
with the final pH adjusted to 7.4.
presence of compounds.
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paring ligand binding to the same h-Tel sequence but with
a different duplex sequence 5′-d[CGA3T3C(CT)2GA3T3
CG]-3′ as comparator. As indicated in Table 1 compound
1 binds potently to the h-Tel (Q) quadruplex (K = 0.83 ×
107 M-1) and an order of magnitude less effectively to the
duplex (D) sequence, with a Q/D ratio of 13.8. Very simi-
lar results were observed with the 3-acetylamino derivative
3 whereas the 2-acetylamino isomer 2 was both the most
potent binder to h-Tel quadruplex and the weakest binder
to duplex DNA, giving a more favourable Q/D ratio of
37.5. The 13-ethyl homologue 8 was a much weaker
binder than the close variant (1) to h-Tel quadruplex (K =
0.06 × 107 M-1) suggesting that steric perturbations im-
posed by the larger ethyl group compromised stacking in-
teractions within the quadruplex structure (see Additional
file 1 for sensorgrams). Quadruplex-ligand interaction was
also explored by Circular Dichroism (CD). Far-UV CD
spectra were collected on 4 μM samples of h-Tel in
110 mM K+ solution (100 mM KCl and 10 mM potassium
phosphate buffer) at pH 7.0 and 298 K. The CD spectrum
was characterised by a strong band at 295 nm with
additional broad positive bands at 250 and 270 nm
[12,13]. The ability of 1 and the two N-acetyl compounds
to bind to these folded structures in K+ solution is shown
in Figure 4a. All three ligands induce stronger ellipticity atFigure 4 Ligand-quadruplex interactions. a: CD spectra of ligands 1 (bla
using the h-Tel sequence 5′-d[AGGG(TTAGGG)3]-3′ are compared to the liga
induce an anti-parallel conformation in the absence of K+ ions. c: The quad
monitoring the h-Tel thermal unfolding at 290 nm. d: Schematic represent
[AGGG(TTAGGG)3]-3′ anti-parallel (2 + 2) basket form and anti-parallel (3 + 1290 nm and a negative band at around 260 nm. These
pronounced spectroscopic changes are consistent with the
ligands perturbing the equilibrium in favour of the basket-
type (2 + 2) anti-parallel quadruplex structure, which is
the predominant species identified for the same sequence
in Na+ solution (Figure 4d) [30-33]. The ligand-induced
interconversion of structures is consistent with stabilisa-
tion of the complex through ligand contacts specific to the
hydrophobic pocket created by the diagonal TTA loop
over the terminal G-tetrad [12,13].
The ability of the three ligands to induce structure in
the single stranded h-Tel sequence in aqueous solution
in the absence of significant concentrations of K+ ions
was also investigated. The unfolded h-Tel sequence at
298 K gives a low intensity positive band in the CD
spectrum at 265 nm (Figure 4b). However, in the pres-
ence of 3.5 molar equivalents of ligand, emergence of
the characteristic band at 290 nm was observed, consist-
ent with the ligand-induced formation of the anti-
parallel structures evident in the K+ buffered solution.
Thus, under both sets of conditions (with and without
stabilising K+ ions), evidence is adduced for ligand select-
ivity for the anti-parallel quadruplex structure [12,13].
This analysis was extended to examine the effects of
ligand binding on thermal stability by measuring the
unfolding curves at 290 nm of the complexes formed inck hashed), 2 (red) and 3 (blue) at 4 μM in 110 mM of K+ at pH 7.0
nd free h-Tel (black) spectra. b: The ability of ligands 1, 2 and 3 to
ruplex stabilising effects of ligands 1, 2 and 3 was carried out by
ation of the intramolecular folded structure of the h-Tel sequence 5′-d
) hybrid form. The arrows indicate strand direction from 5′ to 3′.
Figure 5 Anti-proliferative effect on normal and transformed fibroblasts. a: In vitro growth curves of human transformed (BJ-EHLT) and
normal telomerised (BJ-hTERT) fibroblasts exposed to 0.5 μM of 1 (○), 2 (▲) and 3 (×) or vehicle (□). The number of viable cells was determined
daily. Three independent experiments were evaluated. Error bars indicate SD. b: Histograms show the percentage of growth inhibition of BJ-EHLT
and BJ-hTERT cells treated with 0.5 μM of each compound versus untreated samples at the indicated times.
Figure 6 Activation of DNA damage response. Human transformed BJ-EHLT fibroblasts were treated with 0.5 μM of 1, 2 and 3 for 24 hrs, then
fixed and processed for IF analysis with anti-γH2AX antibody, and counterstained with DAPI to mark nuclei. a: Representative images of IF at 63×
magnification. b: Histograms shows the percentage of γH2AX-positive cells scored by immunofluorescence analysis (*P < 0.05).
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Figure 4a. Monitoring the thermal unfolding transition
for h-Tel produces a sigmoidal unfolding curve with a
transition mid-point Tm value of 72 ± 3°C (Figure 4c).
All three ligands show significant effects in enhancing
the stability of the quadruplex by shifting the Tm values
to higher temperatures (ΔTm ~ 15-19°C compared to h-
Tel without bound ligands) (Table 1).Figure 7 Induction of telomere damage and aberrations. Cells untreate
analysis against TRF1 and γH2AX. a: Representative images of IF were acqu
Enlarged views (2.5×) of treated merged images are reported. Histograms r
of TIFs per nucleus. c: in the untreated (vehicle) and treated cells with the
scored as TIF-positive. d: BJ-EHLT fibroblasts treated with 1, 2 or 3 for 72 hr
for FISH with a telomere specific probe. The average number of specific te
lower panels, representative images of telomere aberrations are shown at 1
μM were fixed and stained with DAPI. Anaphase bridges were scored by co
induction in treated versus untreated samples. Right panels show represen
magnification. Histograms show the mean of three independent experimeBiological effects of quinoacridinum salts
To ascertain if the compounds 2 and 3 maintained the
same biological and molecular features of the previously
described 1, we firstly evaluated their effect on cell pro-
liferation in a panel of different histotype tumor cell
lines, showing that both compounds maintained an anti-
proliferative effect in several human cancer cell lines
(Additional file 1). Selectivity for transformed vs normald or treated with 1, 2 and 3 for 24 hrs were fixed and processed for IF
ired with a Leica deconvolution microscope (magnification 100×).
epresent the Percentage of TIFs-positive cells. b: and average number
indicated compounds. Cells with four or more γH2AX/TRF1 foci were
s at 0.5 μM were blocked in metaphase with colcemide and processed
lomeric aberrations in each sample is reported in the histograms. In the
00× magnification. e: BJ-EHLT treated with 1, 2 or 3 for 24 hrs at 0.5
unting 400 nuclei per sample in triplicate. Histograms show the fold
tative images of anaphase bridges in the treated samples at 63×
nts. Error bars indicate ± SD. (*P < 0.05).
Figure 8 Expression of TRF1, TRF2 and POT1 at the telomere
level: ChIP experiments on BJ-EHLT fibroblasts incubated with
0.5 μM of 1, 2 or 3 for 24 hrs. Precipitations were performed with
antibodies against TRF1, TRF2 and POT1. The total DNA (input)
represents 10% of genomic DNA. a: A representative ChIp
experiment is shown. b: The histogram shows the densitometric
evaluation of three independent experiments, with error bars
indicating ± SD.
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fibroblasts infected or not with the Large T antigen of
SV40. Figure 5a and b shows the growth curves of un-
treated and drug-treated cells, analyzed from day 2 to 8
of culture by using 0.5 μM concentration of each com-
pound, a dose causing cell death when cells are chronic-
ally exposed to the lead compound 1. A time-dependent
decrease of cell proliferation was observed in SV40
transformed (BJ-EHLT) cells treated with the ligands
reaching the maximum effect at day 6 (for the com-
pounds 1 and 2) or seven (compound 3). Interestingly,
as already described for 1, the compounds 2 and 3 did
not induce inhibition of cell proliferation in normal
telomerized fibroblasts, which were unaffected by the
treatment (Figure 5a and b). Even if the mechanism(s) of
selectivity towards transformed cells were not identified
yet, our results indicate that the new-generated agents 2
and 3, similarly to the lead compound, preferentially
limit the growth of cancer cells.
Consequently, the ability of the new-generated G-
quadruplex ligands 2 and 3 to cause telomere uncapping
has been investigated. To this aim, a two-steps analysis
was performed to establish, in a first case, if the com-
pounds are able to induce DNA damage and, secondly,
if the DNA damage is localized at the telomeres. Im-
munofluorescence analysis performed to evaluate the
phosphorylation of H2AX, a hallmark of DNA double-
strand break, showed that all the compounds activated a
DNA damage response pathway (Figure 6a). However,
the quantitative analysis revealed that the compound 2
induced a percentage of cells positive for γH2AX quite
similar to compound 1, while, consistently with the
above reported data on cell proliferation (Figure 5), 3 is
less potent than the lead compound (*P < 0.05), in acti-
vating the damage response pathway.
These results encouraged us to undertake further stud-
ies aimed to investigate the telomere specific effects of
the ligands, analyzing whether γH2AX was phosphory-
lated in response to dysfunctional telomeres. Deconvo-
lution microscopy showed that, similarly to 1, some of
the damaged foci induced by 2 and 3 co-localized with
TRF1, an effective marker for interphase telomeres,
forming so-called Telomere dysfunction Induced Foci
(TIFs) [34] (Figure 7a). Quantitative analysis revealed
that treatment with 2 increased the percentage of cells
with more than four γH2AX/TRF1 co-localizations (in-
dicated as TIF-positive cells), at comparable levels with
respect to 1, while 3 had a significant but less pro-
nounced effect. Consistently with these results, while 1
and 2 induced a superimposable number of TIFs per nu-
cleus (ca. eight) the mean of telomere foci induced by 3
was reduced to six (Figure 7b, c).
To directly evaluate telomere damage elicited by the
different ligands, the telomere status of drug-treated BJ-EHLT was analysed by a fluorescence in situ hybridiza-
tion on metaphase spreads with a telomere specific
fluorescent probe. The cytogenetic analysis revealed that
all the compounds induced a significant increase of fre-
quency of telomere doublets (characterized by a double
telomere signal at chromosome ends) and sister telo-
mere fusions (in which two sister chromatids telomeric
signals are fused into one single spot), while other telo-
mere aberrations (telomere losses and/or deletions) were
not found. However, again telomere aberrations induced
by 2 are quantitatively similar to the lead compound,
while a lower effect was observed upon treatment with
3. As a result of chromosome ends fusion consequent to
telomere damage, chromatin bridges are occasionally ob-
served between daughter cells after mitosis (also called
anaphase bridges). In 1 treated BJ-EHLT, anaphase brid-
ges frequency in a cycling population was ten-fold in-
creased. With a minor extent 2 and 3 were both able to
induce anaphase bridges when administered at the same
dose, closely comparing the effects of the lead com-
pound (Figure 7e).
Finally, the effect of the G-quadruplex ligands on telo-
mere capping has been investigated. Specifically, the ac-
tivity of 2 and 3, in comparison to 1, was analysed on
the localization of TRF1, TRF2, and POT1, three telomeric
proteins that induce telomere dysfunction and evoke
DNA damage signaling when their levels are reduced at
telomeres. ChIP assay showed that all the compounds
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http://www.jeccr.com/content/32/1/68delocalized POT1 from telomeres, (Figure 8a and b), while
TRF1 and TRF2 remained associated with the telomeres
upon treatment.
This response is typical of the telomere deprotection
occurring during cellular senescence or upon the loss of
telomeric proteins [34-40]. The ability of G-quadruplex
ligands to uncap telomeres and to possess anti-tumor
activity has been already described for other agents,
[41-45] reinforcing the notion that these agents can act
as inhibitors of a telomere-related process and therefore
the rationale for the development of this class of inhibi-
tors as anti-tumor agents must be found elsewhere other
than in higher telomerase expression in cancer cells.
Taken collectively our results clearly demonstrate that
compounds 2 (but less efficiently 3) rapidly disrupt telo-
mere architecture of cells, by delocalizing the telomeric
protein POT1, resulting in a potent DNA damage re-
sponse characterized by the formation of several telo-
meric foci.
Furthermore, it is apparent that the 2-substitued
quinoacridinium salt 2 more closely mimics the overall
pharmaceutical profile of the prototypic compound 1
than the regioisomer 3. Our recent synthetic work has
therefore focused on the 2-substituted series and our ef-
forts to maximize on-target and minimize off-target
properties will be reported separately.Conclusions
Molecular modification of quinoacridinum salts 1 have
shown to reduce undesired cardiotoxic effects while
maintaining the on-target features as telomere targeting
agents. This findings provide a strong rational for devel-
opment of this class of compounds as tools for a G-
quadruplex targeted anti-cancer therapy.Additional file
Additional file 1: Cytotoxicity of 2 and 3 and SPR sensorgrams.Competing interests
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